Impel Pharmaceuticals is the first company to investigate targeting the upper nasal space with optimized therapeutic molecules and formulations. As a result, Impel's therapies have the potential to improve the onset of symptomatic relief for a spectrum of conditions.
Impel's mission is to create and provide transformative therapies for people suffering from diseases with high unmet medical needs. We have pioneered an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.
To learn more about Impel Pharmaceuticals, please visit our website at http://impelpharma.com.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTL...
Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer
May 10, 2023
SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs,...
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
May 05, 2023
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announc...